Bethesda, MD – July 6, 2016 – GlySens Incorporated’s presentation entitled “Continuous, Long-term, Fully Implanted Glucose Sensor” was discussed today by Dr. Joseph Lucisano, the Company’s founder and CTO, at the “Fourth Artificial Pancreas Workshop.” This event, held at the National Institutes of Health (NIH) campus, is organized in coordination with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Diabetes Mellitus Interagency Coordinating Committee (DIMCC). The aim is to bring together a multi-disciplinary forum to discuss current and potential future challenges of bringing new artificial pancreas (AP) technologies to individuals with diabetes. Dr. Lucisano discussed the GlySens Eclipse™ ICGM® System and its potential for eventual application in an artificial pancreas.
From the GlySens Presentation Abstract:
Joseph Y. Lucisano, PhD; David A. Gough, PhD GlySens Incorporated; University of California, San Diego
A stable, user-acceptable glucose sensor is an essential component of any AP system. A long-term (>1 year), second generation, fully implanted sensor/telemeter device (Eclipse™ ICGM ® Sensor), developed by GlySens in conjunction with an NIH-funded collaboration between GlySens and UCSD, is currently in clinical trials (ClinicalTrials.gov Identifier NCT02345967). The sensor is based on a reaction catalyzed by glucose oxidase and catalase coupled with electrochemical oxygen detection, which helps ensure immunity to interferents and stability of calibration. The device’s detectors are located on the face of a hermetically-sealed titanium housing containing a battery, potentiostats, logic circuitry, and a telemetry transmitter. The transmitter has a typical minimum range of 12 feet, sending glucose-dependent signals every 3 minutes to an external receiver/display, which handles calculations, alerts, calibration, information relay, etc. The sensor is implanted subcutaneously or exchanged yearly by a simple outpatient procedure using local anesthesia, requires no skin-attached elements, and may require recalibration by finger-stick at most only every few weeks to months.
The fully implanted sensor requires an annual user decision (whether to implant or not) and an occasional decision to recalibrate; no regular user intervention is required to receive glucose readings. This combination of features presents minimal barriers for adherence to continuous glucose monitoring as may be required for various treatment modalities, including AP systems. In contrast, the present percutaneous sensors require multiple daily decisions (to finger-stick or not) and weekly decisions (to insert and replace or not), as well as disadvantages related to percutaneous device management and skin irritation.